These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 38525109)

  • 1. B cell pathway dual inhibition for systemic lupus erythematosus: a prospective single-arm cohort study of telitacicept.
    Ji L; Geng Y; Zhang X; Deng X; Song Z; Tan M; Tan Y; Qu C; Zhang Z
    MedComm (2020); 2024 Apr; 5(4):e515. PubMed ID: 38525109
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Telitacicept, a novel humanized, recombinant TACI-Fc fusion protein, for the treatment of systemic lupus erythematosus.
    Fan Y; Gao D; Zhang Z
    Drugs Today (Barc); 2022 Jan; 58(1):23-32. PubMed ID: 35107091
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Telitacicept for Recalcitrant Cutaneous Manifestations of Systemic Lupus Erythematosus: A Case Report and Review of the Literature.
    Ma X; Fu X; Cui B; Lin H
    Tohoku J Exp Med; 2022 Oct; 258(3):219-223. PubMed ID: 36047131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Telitacicept: First Approval.
    Dhillon S
    Drugs; 2021 Sep; 81(14):1671-1675. PubMed ID: 34463932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Telitacicept as a BLyS/APRIL dual inhibitor for autoimmune disease.
    Shi F; Xue R; Zhou X; Shen P; Wang S; Yang Y
    Immunopharmacol Immunotoxicol; 2021 Dec; 43(6):666-673. PubMed ID: 34519594
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized Phase 2 Trial of Telitacicept in Patients With IgA Nephropathy With Persistent Proteinuria.
    Lv J; Liu L; Hao C; Li G; Fu P; Xing G; Zheng H; Chen N; Wang C; Luo P; Xie D; Zuo L; Li R; Mao Y; Dong S; Zhang P; Zheng H; Wang Y; Qin W; Wang W; Li L; Jiao W; Fang J; Zhang H
    Kidney Int Rep; 2023 Mar; 8(3):499-506. PubMed ID: 36938094
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of telitacicept in refractory systemic lupus erythematosus patients who failed treatment with belimumab : A case series.
    Fan Q; Yang H; Liu Y
    Z Rheumatol; 2024 Jun; 83(5):387-392. PubMed ID: 38157053
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A patient with refractory proliferative lupus nephritis treated with telitacicept: A case report.
    Chen JW; Zhan JY; Liang SP; Wang XD; Lin CS; Xu Q
    Int J Rheum Dis; 2023 Jul; 26(7):1417-1421. PubMed ID: 37218552
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of telitacicept in patients with lupus nephritis: a single-center, real-world retrospective study.
    Huang X; Lin F; Chen H
    Clin Exp Nephrol; 2024 Sep; 28(9):902-909. PubMed ID: 38613741
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Telitacicept in patients with active systemic lupus erythematosus: results of a phase 2b, randomised, double-blind, placebo-controlled trial.
    Wu D; Li J; Xu D; Merrill JT; van Vollenhoven RF; Liu Y; Hu J; Li Y; Li F; Huang C; Wang G; Li X; Zhao J; Zhao D; Huang C; Liu H; Wei W; Shi G; Lu F; Zuo X; Bi L; Li Z; Wang X; Zhang M; Tie N; Li J; Mo H; Fang J; Bao C; Zhang F
    Ann Rheum Dis; 2024 Mar; 83(4):475-487. PubMed ID: 38129117
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of telitacicept therapy in systemic lupus erythematosus with hematological involvement.
    Cheng J; Peng Y; Wu Q; Wu Q; He J; Yuan G
    Clin Rheumatol; 2024 Jul; 43(7):2229-2236. PubMed ID: 38767710
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Refractory lupus hepatitis successfully treated with telitacicept who failed to belimumab: A case report and literature review.
    Fan Q; Ji H; Liu Y; Jia C; Zou L; Yang H
    Lupus; 2024 Apr; 33(4):414-419. PubMed ID: 38320748
    [No Abstract]   [Full Text] [Related]  

  • 13. Efficacy and safety of telitacicept in patients with systemic lupus erythematosus: a multicentre, retrospective, real-world study.
    Jin HZ; Li YJ; Wang X; Li Z; Ma B; Niu L; Wang P; Pan HF; Li SD; Bao W; Wang G; Li XM; Chen Z
    Lupus Sci Med; 2023 Nov; 10(2):. PubMed ID: 38007228
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy and safety of telitacicept for the treatment of systemic lupus erythematosus: a real life observational study.
    Chen R; Fu R; Lin Z; Huang C; Huang W
    Lupus; 2023 Jan; 32(1):94-100. PubMed ID: 36416639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Frequency and predictors for early-achieved lupus low disease activity state in systemic lupus erythematosus patients treated with telitacicept or belimumab: A real-life, single-center observational study.
    Fan C; Yang T; Zheng S; Liao X; Xie R; Chen S; Li J
    Front Immunol; 2024; 15():1423035. PubMed ID: 38947321
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of telitacicept in patients with lupus nephritis.
    Zhu H; Hu HQ; Wei HL; Zhang DX; Yang H; Zhang QK; Jin L
    Exp Ther Med; 2024 Oct; 28(4):371. PubMed ID: 39091632
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Telitacicept for autoimmune nephropathy.
    Cai J; Gao D; Liu D; Liu Z
    Front Immunol; 2023; 14():1169084. PubMed ID: 37342346
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The efficacy of rituximab plus belimumab or telitacicept in refractory lupus nephritis.
    Chen Y; Shi N; Lei X; Ren P; Lan L; Chen L; Wang Y; Xu Y; Lin Y; Chen J; Han F
    Rheumatology (Oxford); 2023 Dec; ():. PubMed ID: 38145455
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Telitacicept: A novel horizon in targeting autoimmunity and rheumatic diseases.
    Zeng L; Yang K; Wu Y; Yu G; Yan Y; Hao M; Song T; Li Y; Chen J; Sun L
    J Autoimmun; 2024 Sep; 148():103291. PubMed ID: 39146891
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of telitacicept, a BLyS/APRIL dual inhibitor, in the treatment of IgA nephropathy: a retrospective case-control study.
    Wang M; Ma J; Yao L; Fan Y
    Clin Kidney J; 2024 Oct; 17(10):sfae285. PubMed ID: 39391591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.